Related Experiment Video
Updated: Jan 22, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?
Shahzad Khan1, Mohammad A Kamal2,3,4
1Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan V, China.
Insights
Wogonin, a plant-derived flavonoid, shows promise in treating diabetic cardiomyopathy (DCM). This review explores its potential therapeutic benefits for cardiovascular complications associated with diabetes mellitus (DM).
Area of Science:
- Pharmacology
- Cardiology
- Natural Products
Background:
- Diabetes Mellitus (DM) causes metabolic derangements, notably leading to diabetic cardiomyopathy (DCM).
- Cardiovascular complications in DM can cause cardiac failure, independent of ischemic heart disease.
- Diabetic cardiomyopathy (DCM) represents a significant health concern in diabetic patients.
Purpose of the Study:
- To review the therapeutic potential of Wogonin for treating diabetic cardiomyopathy (DCM).
- To explore Wogonin's properties and safety profile in the context of cardiovascular disease.
- To highlight Wogonin as a potential plant-derived treatment for DCM.
Main Methods:
- Literature review of studies on Wogonin and its effects.
- Analysis of Wogonin's pharmacological properties, including anti-inflammatory, antioxidant, and anti-apoptotic effects.
- Evaluation of safety and toxicity data for Wogonin.
Main Results:
- Wogonin exhibits antioxidant, anti-inflammatory, anti-viral, and anti-thrombotic properties.
- Wogonin has demonstrated the ability to alleviate apoptosis and ER stress in cells.
- Wogonin possesses a favorable safety profile with minimal organ toxicity.
Conclusions:
- Wogonin shows significant therapeutic potential for managing diabetic cardiomyopathy (DCM).
- Its multifaceted properties, including anti-apoptotic and anti-ER stress effects, are beneficial for cardiovascular health.
- Wogonin represents a promising natural compound for further investigation in DCM treatment.
Abstract:
Diabetes Mellitus (DM) is now a well-known factor which initiates many metabolic derangements in various tissues and organs including liver, muscle, pancreas, adipose tissue, cardiovascular and nervous system. Cardiovascular complications are the most crucial , and their effects are so intensive that their derangement leads to cardiac failure even in the absence of ischemic heart diseases. This entity of cardiac pathology in DM is often regarded as diabetic cardiomyopathy (DCM). Recently, many plant-derived drugs have been tested to control and alleviate DCM. Wogonin is one of the drugs the characteristics of which have been deeply studied. Wogonin is a flavonoid having yellow color pigment in their leaves and is obtained from the roots of plant Scutellaria Baicalensis Georgi. Wogonin has long been used as an active anti-cancer drug in Chinese medicine practice. In recent past wogonin has shown to possess notable anti-inflammatory, and anti-allergic properties. Wogonin has demonstrated to possess anti-oxidant, anti-viral, anti-inflammatory and also anti-thrombotic properties. Wogonin has shown to alleviate apoptosis, and ER stress in the cells and this property can also be used in the treatment of cardiovascular diseases. Notably, wogonin has been documented to have an extensive margin of safety as well as displays little or no organ toxicity following extended intravenous administration. In this review, we discuss recently discovered therapeutic potential of wogonin in the treatment of DCM.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care

